{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:12:55Z","timestamp":1794881575768,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jpsychires.2021.06.041","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:26:27Z","timestamp":1624436787000},"page":"116-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Safety profile of clozapine: Analysis using national registry data in Japan"],"prefix":"10.1016","volume":"141","author":[{"given":"Shinichi","family":"Imazu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-297X","authenticated-orcid":false,"given":"Tetsufumi","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2021.06.041_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajp.2016.01.012","article-title":"FDA changes clozapine monitoring guidelines: implications for worldwide practice","volume":"21","author":"Bastiampillai","year":"2016","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib3","article-title":"Mask off? Lithium augmentation for clozapine rechallenge after neutropenia or agranulocytosis: discontinuation might Be risky","volume":"20","author":"Boazak","year":"2018","journal-title":"Prim. care companion CNS Disord"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","article-title":"When symptoms persist: clozapine augmentation strategies","volume":"27","author":"Buckley","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40263-017-0481-5","article-title":"Clozapine and gastrointestinal hypomotility","volume":"31","author":"Cohen","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-230X-11-17","article-title":"Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study","volume":"11","author":"De Hert","year":"2011","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eurpsy.2010.03.003","article-title":"Second-generation antipsychotics and constipation: a review of the literature","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2020.03.032","article-title":"Constipation screening in people taking clozapine: a diagnostic accuracy study","volume":"220","author":"Every-Palmer","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"16","author":"Ingimarsson","year":"2016","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1620\/tjem.252.177","article-title":"Clinical factors associated with new-onset glucose intolerance among patients with schizophrenia during clozapine treatment: all-case surveillance in Japan","volume":"252","author":"Ishibashi","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.779","article-title":"Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?","volume":"21","author":"Kang","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib15","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2018.03.006","article-title":"Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review","volume":"199","author":"Knoph","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/pgs-2018-0188","article-title":"Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective","volume":"20","author":"Legge","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib19","doi-asserted-by":"crossref","first-page":"e2739","DOI":"10.1002\/hup.2739","article-title":"Clozapine-induced agranulocytosis in Japan: changes in leukocyte\/neutrophil counts before and after discontinuation of clozapine","volume":"35","author":"Matsui","year":"2020","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib21","first-page":"401","article-title":"Real-world antipsychotic treatment practices","volume":"30","author":"Moore","year":"2007","journal-title":"Psychiatr. Clin."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib23","first-page":"40","article-title":"Rediscovering clozapine: adverse effects develop-What should you do now?","volume":"15","author":"Newman","year":"2016","journal-title":"Curr. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/sbq137","article-title":"Risk factors for ileus in patients with schizophrenia","volume":"38","author":"Nielsen","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib26","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases","volume":"69","author":"Palmer","year":"2008","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/104012371502700404","article-title":"The risk of suicide after clozapine discontinuation: cause for concern","volume":"27","author":"Patchan","year":"2015","journal-title":"Ann. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2036.1993.tb00087.x","article-title":"Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome","volume":"7","author":"Prior","year":"1993","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.euroneuro.2015.11.006","article-title":"An observational study of clozapine induced sedation and its pharmacological management","volume":"26","author":"Ramos Perdigu\u00e9s","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.biopsych.2015.12.006","article-title":"Pharmacogenomic study of clozapine-induced agranulocytosis\/granulocytopenia in a Japanese population","volume":"80","author":"Saito","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060863","article-title":"Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis","volume":"17","author":"Shirazi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12888-015-0578-7","article-title":"An evaluation of variation in published estimates of schizophrenia prevalence from 1990\u25002013: a systematic literature review","volume":"15","author":"Simeone","year":"2015","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib36","doi-asserted-by":"crossref","first-page":"113764","DOI":"10.1016\/j.psychres.2021.113764","article-title":"A descriptive study of 10-year clozapine use from the nationwide database in Japan","volume":"297","author":"Toyoda","year":"2021","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.30773\/pi.2020.0376","article-title":"Clozapine is better tolerated in younger patients: risk factors for discontinuation from a nationwide database in Japan","volume":"18","author":"Toyoda","year":"2021","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.psychres.2019.01.110","article-title":"Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia","volume":"275","author":"Ucok","year":"2019","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","article-title":"Clozapine-related EEG changes and seizures: dose and plasma-level relationships","volume":"1","author":"Varma","year":"2011","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2008.06.088","article-title":"Clozapine-induced myocarditis: role of catecholamines in a murine model","volume":"592","author":"Wang","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0140-6736(05)72452-1","article-title":"Clozapine and sudden death","volume":"355","author":"Warner","year":"2000","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib44","first-page":"1185","article-title":"Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity","volume":"166","author":"Wooltorton","year":"2002","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.jpsychires.2021.06.041_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S2045796015000694","article-title":"Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia","volume":"25","author":"Xiang","year":"2016","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.jpsychires.2021.06.041_bib46","doi-asserted-by":"crossref","first-page":"112271","DOI":"10.1016\/j.psychres.2019.02.056","article-title":"Clozapine prescription pattern in patients with schizophrenia in Asia: the REAP survey (2016)","volume":"287","author":"Xu","year":"2020","journal-title":"Psychiatr. Res."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:21:13Z","timestamp":1758367273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395621004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":46,"alternative-id":["S0022395621004155"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.06.041","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of clozapine: Analysis using national registry data in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}